Incidence of deep vein thrombosis is increased with 30 mg twice daily dosing of enoxaparin compared with 40 mg daily

Gordon M. Riha, Philbert Van, Jerome A. Differding, Martin Schreiber

    Research output: Contribution to journalArticle

    11 Citations (Scopus)

    Abstract

    BACKGROUND: The purpose of this study was to analyze whether 2 standard dosing regimens of enoxaparin (30 mg twice daily vs 40 mg once daily) would result in different deep vein thrombosis (DVT) rates and anti-factor Xa activity (anti-Xa) in surgical patients. METHODS: Patients who required enoxaparin for prophylaxis were followed prospectively. Demographics were recorded. Patients underwent standardized duplex screening. Peak anti-Xa levels were drawn on 4 consecutive days. RESULTS: Sixty-three patients were followed up (28 patients on 30 mg twice daily, 35 patients on 40 mg once daily). There was no significant difference in demographics between groups. Twenty-five percent of patients on 30 mg twice daily developed a DVT, whereas 2.9% of patients on 40 mg once daily developed a DVT. Patients on 30 mg twice daily had significantly lower anti-Xa levels. CONCLUSIONS: The incidence of DVT is increased in surgical patients who receive 30 mg twice daily dosing of enoxaparin compared with 40 mg daily. Dosing of 40 mg once daily results in significantly higher peak anti-Xa levels compared with 30 mg twice daily.

    Original languageEnglish (US)
    Pages (from-to)598-601
    Number of pages4
    JournalAmerican Journal of Surgery
    Volume203
    Issue number5
    DOIs
    StatePublished - May 2012

    Fingerprint

    Enoxaparin
    Venous Thrombosis
    Incidence
    Factor Xa
    Demography

    Keywords

    • 30 BID
    • 40 QD
    • DVT
    • Enoxaparin
    • Surgery
    • Thrombosis

    ASJC Scopus subject areas

    • Surgery

    Cite this

    Incidence of deep vein thrombosis is increased with 30 mg twice daily dosing of enoxaparin compared with 40 mg daily. / Riha, Gordon M.; Van, Philbert; Differding, Jerome A.; Schreiber, Martin.

    In: American Journal of Surgery, Vol. 203, No. 5, 05.2012, p. 598-601.

    Research output: Contribution to journalArticle

    @article{fc50f1c1339b4851a5355f6afaa2c561,
    title = "Incidence of deep vein thrombosis is increased with 30 mg twice daily dosing of enoxaparin compared with 40 mg daily",
    abstract = "BACKGROUND: The purpose of this study was to analyze whether 2 standard dosing regimens of enoxaparin (30 mg twice daily vs 40 mg once daily) would result in different deep vein thrombosis (DVT) rates and anti-factor Xa activity (anti-Xa) in surgical patients. METHODS: Patients who required enoxaparin for prophylaxis were followed prospectively. Demographics were recorded. Patients underwent standardized duplex screening. Peak anti-Xa levels were drawn on 4 consecutive days. RESULTS: Sixty-three patients were followed up (28 patients on 30 mg twice daily, 35 patients on 40 mg once daily). There was no significant difference in demographics between groups. Twenty-five percent of patients on 30 mg twice daily developed a DVT, whereas 2.9{\%} of patients on 40 mg once daily developed a DVT. Patients on 30 mg twice daily had significantly lower anti-Xa levels. CONCLUSIONS: The incidence of DVT is increased in surgical patients who receive 30 mg twice daily dosing of enoxaparin compared with 40 mg daily. Dosing of 40 mg once daily results in significantly higher peak anti-Xa levels compared with 30 mg twice daily.",
    keywords = "30 BID, 40 QD, DVT, Enoxaparin, Surgery, Thrombosis",
    author = "Riha, {Gordon M.} and Philbert Van and Differding, {Jerome A.} and Martin Schreiber",
    year = "2012",
    month = "5",
    doi = "10.1016/j.amjsurg.2011.12.008",
    language = "English (US)",
    volume = "203",
    pages = "598--601",
    journal = "American Journal of Surgery",
    issn = "0002-9610",
    publisher = "Elsevier Inc.",
    number = "5",

    }

    TY - JOUR

    T1 - Incidence of deep vein thrombosis is increased with 30 mg twice daily dosing of enoxaparin compared with 40 mg daily

    AU - Riha, Gordon M.

    AU - Van, Philbert

    AU - Differding, Jerome A.

    AU - Schreiber, Martin

    PY - 2012/5

    Y1 - 2012/5

    N2 - BACKGROUND: The purpose of this study was to analyze whether 2 standard dosing regimens of enoxaparin (30 mg twice daily vs 40 mg once daily) would result in different deep vein thrombosis (DVT) rates and anti-factor Xa activity (anti-Xa) in surgical patients. METHODS: Patients who required enoxaparin for prophylaxis were followed prospectively. Demographics were recorded. Patients underwent standardized duplex screening. Peak anti-Xa levels were drawn on 4 consecutive days. RESULTS: Sixty-three patients were followed up (28 patients on 30 mg twice daily, 35 patients on 40 mg once daily). There was no significant difference in demographics between groups. Twenty-five percent of patients on 30 mg twice daily developed a DVT, whereas 2.9% of patients on 40 mg once daily developed a DVT. Patients on 30 mg twice daily had significantly lower anti-Xa levels. CONCLUSIONS: The incidence of DVT is increased in surgical patients who receive 30 mg twice daily dosing of enoxaparin compared with 40 mg daily. Dosing of 40 mg once daily results in significantly higher peak anti-Xa levels compared with 30 mg twice daily.

    AB - BACKGROUND: The purpose of this study was to analyze whether 2 standard dosing regimens of enoxaparin (30 mg twice daily vs 40 mg once daily) would result in different deep vein thrombosis (DVT) rates and anti-factor Xa activity (anti-Xa) in surgical patients. METHODS: Patients who required enoxaparin for prophylaxis were followed prospectively. Demographics were recorded. Patients underwent standardized duplex screening. Peak anti-Xa levels were drawn on 4 consecutive days. RESULTS: Sixty-three patients were followed up (28 patients on 30 mg twice daily, 35 patients on 40 mg once daily). There was no significant difference in demographics between groups. Twenty-five percent of patients on 30 mg twice daily developed a DVT, whereas 2.9% of patients on 40 mg once daily developed a DVT. Patients on 30 mg twice daily had significantly lower anti-Xa levels. CONCLUSIONS: The incidence of DVT is increased in surgical patients who receive 30 mg twice daily dosing of enoxaparin compared with 40 mg daily. Dosing of 40 mg once daily results in significantly higher peak anti-Xa levels compared with 30 mg twice daily.

    KW - 30 BID

    KW - 40 QD

    KW - DVT

    KW - Enoxaparin

    KW - Surgery

    KW - Thrombosis

    UR - http://www.scopus.com/inward/record.url?scp=84859910803&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84859910803&partnerID=8YFLogxK

    U2 - 10.1016/j.amjsurg.2011.12.008

    DO - 10.1016/j.amjsurg.2011.12.008

    M3 - Article

    VL - 203

    SP - 598

    EP - 601

    JO - American Journal of Surgery

    JF - American Journal of Surgery

    SN - 0002-9610

    IS - 5

    ER -